Surgical Resection, Pharmacodynamic Assays, and Methimazole for Glioblastoma
This trial is testing a drug, Methimazole, to see if it can safely treat brain tumors. It will be given to study participants in increasing doses until side effects occur.
- Brain Tumor
1 Primary · 0 Secondary · Reporting Duration: Up to 6 months after treatment
1 Treatment Group
Surgical Resection, Pharmacodynamic Assays, and Methimazole
1 of 1
19 Total Participants · 1 Treatment Group
Primary Treatment: Surgical Resection, Pharmacodynamic Assays, and Methimazole · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 14 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there opportunities for interested parties to join this research initiative?
"According to clinicaltrials.gov, this medical experiment is actively searching for volunteers. The trial was initially listed on March 1st 2023 and has since been revised as of the 9th of that same month." - Anonymous Online Contributor
How many volunteers are currently enrolled in this medical experiment?
"Affirmative, the clinicaltrials.gov website mentions that this project is currently seeking participants. This research was initially published on March 1st 2023 and has been revised as recently as September 3rd of the same year. 19 people are required to join at one single site." - Anonymous Online Contributor
How perilous is it for people to undergo Surgical Resection, Pharmacodynamic Assays, and Methimazole?
"As this is a Phase 2 trial and there are only data confirming the safety of Surgical Resection, Pharmacodynamic Assays, and Methimazole, it received an assessment score of 2." - Anonymous Online Contributor